Special Issue

Psychoneurobiology Research and Personalized Treatment of Schizophrenia

Message from the Guest Editor

Besides the development of innovative compounds, there has been a trend towards non-pharmacological therapeutics, e.g., cognitive rehabilitation and neuromodulation (e.g., non-invasive brain stimulation) targeting schizophrenia. Further investigations into neurofeedback and environmental factors are also warranted. It is noteworthy that the effects of these treatment modalities have been related to biological markers provided by neurophysiological, neurochemical and structural/functional brain imaging methods. This Special Issue will provide a forum for researchers interested in the phenomenology, underlying mechanisms and treatment of schizophrenia. Contributions will include, but not be limited to, papers dealing with genetic, molecular, imaging, physiological, psychological and behavioral issues. Overall, the information in this Special Issue will facilitate the development of personal therapeutics of greater clinical value.

Guest Editor

Dr. Tomiki Sumiyoshi

National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan

Deadline for manuscript submissions

closed (30 June 2021)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/54378

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

